Anika Therapeutics (ANIK) Expected to Post Earnings on Friday

Key Points

• Anika Therapeutics is expected to report Q3 2026 results before market open on Friday, November 6. Analysts forecast earnings of $0.42 per share and revenue of $29.44 million.
• The company exceeded expectations in its previous quarter, reporting $0.42 EPS versus the $0.03 consensus estimate and revenue of $32.61 million, above forecasts of $29.21 million.
• Analyst sentiment is mixed, with two Buy ratings, one Hold and one Sell; the average price target is $22.00, compared with the stock’s recent price of $21.79.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Anika Therapeutics to post earnings of $0.42 per share and revenue of $29.44 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:30 AM ET.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.39. Anika Therapeutics had a negative net margin of 3.14% and a positive return on equity of 0.20%. The company had revenue of $32.61 million during the quarter, compared to analysts' expectations of $29.21 million. On average, analysts expect Anika Therapeutics to post $0.14 EPS for the current fiscal year and $0.29 EPS for the next fiscal year.

Anika Therapeutics Stock Performance

ANIK opened at $21.79 on Friday. The company has a fifty day moving average price of $20.67 and a two-hundred day moving average price of $15.97. The firm has a market capitalization of $291.55 million, a PE ratio of 1,077.50, a P/E/G ratio of 15.39 and a beta of 0.21. Anika Therapeutics has a 52 week low of $9.01 and a 52 week high of $22.88.

Analysts Set New Price Targets

Several brokerages recently issued reports on ANIK. B. Riley Financial started coverage on shares of Anika Therapeutics in a research note on Friday, September 18th. They issued a "buy" rating and a $23.00 target price for the company. Barrington Research set a $21.00 price objective on Anika Therapeutics in a research note on Thursday, July 30th. Wall Street Zen raised Anika Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 1st. Zacks Research downgraded Anika Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 28th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Anika Therapeutics in a report on Monday, September 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $22.00.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.

Anika's orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.